MRG003 Combined With Immunotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial

NCT07381699 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Cancinoma (NPC)

Interventions

DRUG: Becotatug Vedotin and Pucotenlimab

Sponsor

West China Hospital